Osteoarthritis (OA) is a condition affecting the whole joint and is a major cause of pain and disability worldwide. Although OA is very common, the initial steps which lead to the development of pain and tissue damage are not fully understood. In this study participants will be investigated for markers in the blood, joint and urine in people who have a diagnosis of osteoarthritis or inflammatory arthritis and are receiving a steroid injection for their condition. Markers will be evaluated in participants with osteoarthritis compared with other types of arthritis, including rheumatoid arthritis and spondyloarthritis.

NCT03533569

Conditions

1. Osteoarthritis, Knee
2. Rheumatoid Arthritis
3. Spondyloarthritis
4. Psoriatic Arthritis

Interventions

1. Procedure: Intra-articular corticosteroid injection

MeSH:Arthritis Arthritis, Psoriatic Osteoarthritis, Knee Spondylarthritis

HPO:Arthritis Knee osteoarthritis Polyarticular arthritis

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747

Conditions

1. Rheumatoid Arthritis
2. Psoriatic Arthritis
3. Axial Spondyloarthritis
4. Systemic Lupus Erythematosus
5. Giant Cell Arteritis

Interventions

1. Other: COVID-19 infection

MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases

HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

NCT04345159

Conditions

1. SARS-CoV-2
2. Systemic Lupus Erythematosus
3. Rheumatoid Arthritis
4. Sjogren's Syndrome
5. Psoriatic Arthritis

Interventions

1. Other: Questionnaire by phone call

MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases

HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking anti-malarial medications compared to those who do not. This registry includes approximately 2500 northern Alberta patients with inflammatory arthritis who receive highly complex therapies which may be associated with side effects. This program of data collection and research has been evaluating the effectiveness and safety as well as associated health care costs of rheumatoid and psoriatic arthritis patients since 2004. The principle investigators are based at the University of Alberta while the co-investigators are academic rheumatologists at the University of Alberta. The registry has approximately 900 patients taking anti-malarials combined with their complex therapies and ~ 1500 not on anti-malarials in combination with their complex therapies. We aim to perform a case control study evaluating the impact of anti-malarial drugs (eg. hydroxychloroquine and chloroquine) on the development of COVID-19 compared to those patients who are not on anti-malarial drugs over the next 6-12 months. In addition to frequent e-mail surveys screening for the clinical symptoms of COVID-19 and understanding their concomitant arthritis medication use, we will compare the healthcare outcomes of both groups of arthritis patients with and without COVID-19 for the duration of the pandemic. This information will provide critical information beyond an anecdotal level on whether or not anti-malarials truly provide a protective benefit against COVID-19 or reduce the severity of infection. A blood sample from all participants (Covid-19 positive and negative) will be drawn approximately six months into the study for measurement of antibodies to Covid-19 and possible blood types and HLA alleles. Additionally, this study will be linked to another study "Persistence of SARS-Cov2 in immunocompromised patients" which will specifically evaluate COVID-19 serology and nasopharyngeal swab findings in the subset of patients who develop COVID-19.

NCT04347798

Conditions

1. Covid-19 Infection
2. Rheumatoid Arthritis
3. Psoriatic Arthritis
4. Hydroxychloroquine

Interventions

1. Other: Hydroxychloroquine/Chloroquine

MeSH:Infection Communicable Diseases Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

NCT04351399

Conditions

1. Sars-CoV2
2. Rheumatic Diseases
3. Rheumatoid Arthritis
4. Chronic Pain

Interventions

1. Other: questionnaire assesment

MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain

HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective. This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus. When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.

NCT04363047

Conditions

1. SARS Virus

Interventions

1. Other: 40ml blood sample

MeSH:Arthritis

HPO:Arthritis Polyarticular arthritis

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

NCT04389320

Conditions

1. Rheumatoid Arthritis

Interventions

1. Drug: Hydroxychloroquine

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

NCT04393233

Conditions

1. Rheumatoid Arthritis
2. COVID

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

NCT04397237

Conditions

1. COVID-19
2. Systemic Lupus Erythematosus
3. Sjogren's Syndrome
4. Axial Spondyloarthritis
5. Rheumatoid Arthritis
6. Giant Cell Arteritis

MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases

HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.

NCT04407559

Conditions

1. COVID-19
2. Rheumatoid Arthritis

Interventions

1. Other: Serological analyses to be lead on a pre-existing biobank

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.

NCT04407923

Conditions

1. Juvenile Idiopathic Arthritis
2. COVID 19
3. Treatment

MeSH:Arthritis Arthritis, Juvenile

HPO:Arthritis Polyarticular arthritis

Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.

NCT04434118

Conditions

1. Rheumatoid Arthritis
2. COVID

Interventions

1. Drug: Traditional antirheumatic drugs

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis. Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.

NCT04512001

Conditions

1. Rheumatoid Arthritis

Interventions

1. Drug: MSB11456
2. Drug: EU-approved RoActemra

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

A better understanding of the different phenotypes of COVID 19 in patients with inflammatory rheumatisms, and the persitence of antibodies against SARS CoV-2 in these patients under immunosuppressive drugs are required to propose appropriated recommendations for these patients in order to guide the strategy of vaccination in this immune-depressed population who is not immunized.

NCT04530682

Conditions

1. Rheumatoid Arthritis

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The COVID-19 outbreak has affected health care of patients with rheumatic diseases; telemedicine might help to assist patients. The primary objective is to determine if a hybrid medical care model, which consists of alternating face-to-face medical visits and video medical consultations, is not inferior, in terms of the Patient Reported Outcomes measures (PROMs), to the face-to-face medical care model, among rheumatoid arthritis (RA) outpatients. We also aim to investigate if adherence to RA-related treatment (considered a surrogate of patient´s education) might be improved when patients are re-integrated to the health care system, irrespective of the health care model. In Mexico, COVID-19 pandemic still uncontrolled. Our Institution provides health care to 1500 RA patients/year and up to August 2020, it is estimated that 500 RA patients might be affected, which is our target audience. Reinstalling institutional health care provision is challenging. This a non-inferiority, cross-over study, with 2 intervention arms. Patients will be randomized to 1. Six months of usual medical care model, followed by 4 months of a control period, and 6 months of hybrid medical care model, or 2. Six months of hybrid medical care model, followed by 4 months of a control period, and 6 months of usual medical care model. The following PROMs will be assessed at specific time points: disease activity/disease severity (RAPID-3), disability (HAQ-DI), quality of life (WHOQOL-BREF), patient satisfaction with the medical care model (questionnaire locally developed), patient´s adherence to medical care (missed scheduled visits) and patient´s adherence to RA-related treatment (the Compliance-Questionnaire).

NCT04558905

Conditions

1. Rheumatoid Arthritis
2. Telehealth

Interventions

1. Other: Face-to-face medical visits
2. Other: Alternating face-to-face medical visits and video medical consultations

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly. The dose will be increased to 50 mg if the dose escalation criteria are met during the dose escalation phase of the study.

NCT04559412

Conditions

1. Rheumatoid Arthritis

Interventions

1. Device: Sofusa DoseConnect
2. Drug: Enbrel

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).

NCT04577781

Conditions

1. Arthritis, Rheumatoid

Interventions

1. Drug: GLPG3970
2. Drug: Placebo

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.

NCT04584541

Conditions

1. Spondyloarthritis
2. Rheumatoid Arthritis
3. Covid19

Interventions

1. Biological: blood tests
2. Biological: Nasopharyngeal swabs
3. Biological: Stools

MeSH:Arthritis Arthritis, Rheumatoid Spondylarthritis

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.

NCT04608344

Conditions

1. Rheumatoid Arthritis

Interventions

1. Drug: Atorvastatin
2. Drug: Pravastatin
3. Drug: Rosuvastatin
4. Drug: Filgotinib

MeSH:Arthritis Arthritis, Rheumatoid

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

NCT04655612

Conditions

1. COVID-19
2. SARS-CoV Infection
3. Rheumatoid Arthritis
4. Spondyloarthritis
5. Ankylosing Spondylitis
6. Psoriatic Arthritis

MeSH:Infection Communicable Diseases Spondylitis Coronavirus Infections Severe Acute Respiratory Syndrome Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Spondylitis, Ankylosing Rheumatic Diseases Spondylarthritis Collagen Diseases

HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis